Date: October 08, 2026
Fundraising / Financing
Krsnaa Diagnostics Limited has received in-principle approval from both BSE Limited and National Stock Exchange of India Limited for a preferential issue of convertible warrants to promoters and promoter group.
Approval Details:
- Number of warrants: 16,21,000
- Conversion terms: Each warrant convertible into 1 equity share
- Face value: ₹5 per share
- Issue price: ₹566 per warrant
- Recipients: Promoter and Promoter Group of the Company
- Regulatory basis: SEBI (LODR) Regulations, 2015, Regulation 28(1)
Exchange Approval References:
- BSE Limited approval letter no.: LOD/PREF/PB/FIP/908/2026-27
- NSE approval letter no.: NSE/LIST/56990
Status Update:
The in-principle approval letter received from BSE contains certain factual errors that require rectification. The company will intimate the corrected letter to the exchanges separately upon receipt. The NSE approval letter is enclosed with this filing.
Additional Information:
The information will be available on the company's website at https://krsnaadiagnostics.com/investors/.